4.1 Review

Insulin dysfunction and allostatic load in bipolar disorder

期刊

EXPERT REVIEW OF NEUROTHERAPEUTICS
卷 11, 期 7, 页码 1017-1028

出版社

TAYLOR & FRANCIS LTD
DOI: 10.1586/ERN.10.185

关键词

allostatic load; bipolar disorder; cognition; cytokines; early life stress; general medical comorbidities; HPA; insulin; neuroplasticity; oxidative stress

资金

  1. Stanley Medical Research Institute
  2. National Alliance for Research on Schizophrenia and Depression (NARSAD)
  3. Eli Lilly
  4. Janssen-Ortho
  5. Shire
  6. AstraZeneca
  7. Pfizer
  8. Bristol-Myers Squibb

向作者/读者索取更多资源

Bipolar disorder (BD) is associated with substantial morbidity, as well as premature mortality. Available evidence indicates that 'stress-sensitive' chronic medical disorders, such as cardiovascular disease, obesity and Type 2 diabetes mellitus, are critical mediators and/or moderators of BD. Changes in physiologic systems implicated in allostasis have been proposed to impact brain structures and neurocognition, as well as medical comorbidity in this population. For example, abnormalities in insulin physiology, for example, insulin resistance, hyperinsulinemia and central insulinopenia, are implicated as effectors of allostatic load in BD. Insulin's critical role in CNS physiological (e.g., neurotrophism and synaptic plasticity) and pathophysiological (e.g., neurocognitive deficits, pro-apoptosis and amyloid deposition) processes is amply documented. This article introduces the concept that insulin is a mediator of allostatic load in the BD and possibly a therapeutic target.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.1
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据